Search clinical trials for: BI 2536 BS, intravenous

Total 71 results

Boehringer Ingelheim

Completed

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

Neoplasms
Boehringer Ingelheim

Completed

BI 2536 Second Line Monotherapy in SCLC

Carcinoma, Small Cell

United States, Canada
Boehringer Ingelheim

Completed

BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

Leukemia, Myeloid, Acute

Austria, Germany
Boehringer Ingelheim

Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma

United States
Boehringer Ingelheim

Completed

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Pancreatic Neoplasms

Austria, Germany
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Germany
Boehringer Ingelheim

Completed

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Neoplasms
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

Phase II Study of BI 2536 in Prostate Cancer

Prostatic Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
European Organisation for Research and Treatment...

Completed

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Endometrial Cancer | Melanoma (Skin)

Belgium
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Withdrawn

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

COVID-19
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Terminated

Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Neoplasms
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Healthy
Haukeland University Hospital

Completed

Hypertonic Saline-hetastarch in Cardiac Surgery (HH)

Postoperative Cardiorespiratory Failure

Norway
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How the Body Takes up BI 1467335

Healthy

Netherlands
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body

Healthy Volunteers

Netherlands
Boehringer Ingelheim

Terminated

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

COVID-19

United States, Spain
Boehringer Ingelheim

Completed

Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers

Healthy
Pfizer

Completed

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Psoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic Psoriasis

Japan
Pfizer

Completed

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Crohn's Disease | Ulcerative Colitis

Japan
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

Healthy
Sangart

Completed

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Ischemia | Hypotension

Netherlands, Belgium, Czech Republic, Sweden, Poland, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Pfizer

Active, not recruiting

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

Rheumatoid Arthritis

Japan
Boehringer Ingelheim

Completed

Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers

Healthy
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Solid Tumors, KRAS Mutation

Spain, United Kingdom, United States, Belgium
Boehringer Ingelheim

Active, not recruiting

A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men

Healthy

Germany
Boehringer Ingelheim

Completed

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Terminated

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers

Healthy
Engelhard Arzneimittel GmbH & Co.KG
ClinCompetence Cologne GmbH

Completed

Sinolpan® Pharmacy Non-interventional Study - Quality of Live

Bronchitis | Rhinosinusitis Chronic | Rhinosinusitis Acute

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

A Study to Test How Healthy Men Tolerate Different Doses of BI 1595043

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321

Healthy Volunteers

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test How Well Different Doses of BI 1323495 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam

Healthy

Belgium
Boehringer Ingelheim

Completed

This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357

Healthy | Psoriasis

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 1358894 Affects the Way the Body Breaks Down Midazolam

Healthy

Germany
Boehringer Ingelheim

Withdrawn

A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine

Healthy

3

Subscribe